Tempest Therapeutics, Inc.
TPST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001544227
No open-market purchases or sales by Tempest Therapeutics, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.44M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Tempest Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 22 | 1 | 19 | −2 |
| Shares | 2.20M | 5.36K | 2.35M | +159.5K (+7.3%) |
| Value | $31.8M | $78.0K | $12.4M | −$19.3M (−60.9%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Tempest Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tower Research Capital LLC (TRC) | 2,744 | $15.0K | 0.00% |
| EverSource Wealth Advisors, LLC | 4 | $0 | 0.00% |
Sold out (4)
Institutions that held Tempest Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Foresite Capital Management IV, LLC | 190,213 | $2.75M |
| Monashee Investment Management LLC | 60,000 | $868.0K |
| UBS Group AG | 983 | $14.0K |
| Atlas Private Wealth Advisors | 7 | $0 |
Not filed for Q4 2021 yet (1)
Institutions that held Tempest Therapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Knott David M | 5,359 | $78.0K |